Sermorelin weight-loss evidence
Does sermorelin help with weight loss?
The human studies that tracked body weight found no weight loss with sermorelin. A six-week study in eleven older men found no change in weight, body mass index, waist-to-hip ratio or measured fat. A 16-week trial of a closely related analogue in 19 adults aged 55 to 71 left body weight unaffected and reported more lean mass in men, with no loss of fat. Sermorelin has never been FDA-approved for weight loss, and the sermorelin sold online is compounded. The fat-loss figures quoted in marketing usually come from other drugs: tesamorelin in adults with HIV, and semaglutide in adults with obesity.
Sets the two human sermorelin studies that measured body weight beside the tesamorelin and semaglutide trials they are often confused with, using each trial's own numbers. It is a bounded source review, not a systematic review or individual medical advice.
Weight change in studies
None in a six-week or a 16-week study
FDA approval for weight loss
None, past or present
Where fat-loss figures come from
Tesamorelin and semaglutide trials
Swipe the evidence table sideways to read every column.
| Drug | Who was studied | How long | Result for weight or fat |
|---|---|---|---|
| Sermorelin, nightly | 11 healthy men aged 64 to 76 | Six weeks | No change in weight, body mass index, waist-to-hip ratio or scan-measured fat |
| Sermorelin analogue, nightly | 19 adults aged 55 to 71 | 16 weeks after a four-week placebo period | Body weight unaffected; lean mass rose in men only; no other body-composition change |
| Tesamorelin 2 mg, daily | 412 adults with HIV and abdominal fat accumulation | 26 weeks | Visceral fat fell 15.2%, against a 5.0% rise on placebo |
| Semaglutide 2.4 mg, weekly | 1,961 adults with overweight or obesity | 68 weeks | Mean body weight fell 14.9%, against 2.4% on placebo |
Does sermorelin cause weight loss in human studies?
Not in the studies that measured it. Eleven healthy men aged 64 to 76 injected sermorelin nightly for six weeks, and their weight, body mass index, waist-to-hip ratio and scan-measured muscle and fat did not change. In a 16-week trial of a closely related analogue, 19 adults aged 55 to 71 saw no change in body weight.
Both studies were small and short, and neither enrolled people who were trying to lose weight. They cannot rule out an effect in other groups. They also give no support to the weight-loss results some clinics advertise.
Does sermorelin burn belly fat?
It has not been shown to. The six-week study measured fat by DEXA scan and by waist-to-hip ratio and found no change. The 16-week analogue trial reported more lean mass in men and no other change in body composition.
The belly-fat evidence people quote belongs to tesamorelin. In a 26-week trial of 412 adults with HIV and abdominal fat accumulation, visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo. Tesamorelin is a different drug, and its FDA approval is limited to adults with HIV who have lipodystrophy.
Is sermorelin like Ozempic?
No. Ozempic is semaglutide, a GLP-1 medicine approved for type 2 diabetes, and Wegovy is the semaglutide product approved to reduce excess body weight. Sermorelin is a growth hormone-releasing hormone analogue and works through a different pathway.
In the STEP 1 trial, 1,961 adults with overweight or obesity lost a mean 14.9% of body weight over 68 weeks on semaglutide 2.4 mg, against 2.4% on placebo. No sermorelin study has reported a result like that. If weight loss is the goal, GLP-1 programs are the relevant comparison.
Why do clinics advertise sermorelin for weight loss?
The reasoning is indirect. Growth hormone influences body composition, sermorelin raises growth hormone release, and the 16-week analogue trial found more lean mass in men. Marketing extends that chain to fat loss.
The studies stop one step short. They show a hormone response and, in men, a lean-mass change. None shows a lower body weight or less fat.
What should you check before paying for sermorelin?
Check what the product is and what the plan commits you to. Online sermorelin is compounded, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Prices are often introductory, and some plans bill several months at once.
Ask the prescribing clinician which outcome the treatment is expected to change for you and how it will be measured. Longevity Ranked's price comparison lists each plan's first payment, renewal price and any fees that remain unconfirmed.
Where can I compare current sermorelin providers?
The pages below compare public product and contract information. Some are labeled partner links. Any commission we receive does not change evidence claims or table order.
Partner link; we may earn a commission. Editorial order and findings do not change.
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.
Which sources support this answer?
Sources were checked October 11, 2026. They define the product, population and evidence limits used above; they do not determine individual suitability.
- PubMed: six-week GHRH study in eleven older men
- PubMed: 16-week GHRH(1-29) analogue trial in 19 adults aged 55 to 71
- PubMed: 26-week tesamorelin trial in 412 adults with HIV
- FDA: Egrifta (tesamorelin) prescribing information
- PubMed: STEP 1 trial of semaglutide 2.4 mg in 1,961 adults
- DailyMed: Wegovy (semaglutide) prescribing information
- FDA: understanding the risks of compounded drugs
- DailyMed: Ozempic (semaglutide) prescribing information
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.